About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Dual Immunotherapy for Treatment of Mesothelioma Patients

by Samhita Vitta on August 8, 2020 at 4:30 PM
Font : A-A+

Dual Immunotherapy for Treatment of Mesothelioma Patients

Combination of nivolumab and ipilimumab improved overall survival of patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy, according to a study.

The research is presented at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.The study is presented by Paul Baas, M.D., from The Netherlands Cancer Institute and The University of Leiden, in Amsterdam.

Advertisement


Nivolumab is an immunotherapy that works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.

Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Advertisement

When administered in combination, this dual immunotherapy has shown clinical benefit in 6 different tumor types, including mesothelioma.

Malignant pleural mesothelioma is a highly aggressive cancer with a five-year survival rate of less than 10 percent. Current standard of care treatment is chemotherapy with few treatment advances in the last 15 years.

In this large phase III study, Dr. Baas and the global study investigators randomly assigned more than 600 patients: 303 to the nivolumab + ipilimumab arm and 302 to the chemotherapy arm.

The study had a minimal follow up of close to two years. Two-year overall survival rates were 40.8% for the patients in the experimental treatment arm vs 27.0% in chemotherapy arm.

Of the 30.3% of patients in the study-combination group who experienced grade 3-4 adverse events, 15% discontinued therapy compared with 7.4% of the 32.0% of patients in chemotherapy group.

"CheckMate 743 met its primary endpoint of statistically improved OS with nivolumab + ipilimumab vs standard of care chemotherapy in first-line treatment of patients with mesothelioma," said Dr. Baas. "These clinically meaningful data represent the first positive phase 3 trial of immunotherapy in first-line MPM and should be considered as a new standard of care."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Black Tea Protects against Blood Pressure and Heart Diseases
Green Mediterranean Diet may Help Repair Age-Related Brain Damages
Cervical Cancer Awareness Month 2022
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Lung Cancer Mesothelioma Immunisation Silent Killer Diseases Asbestosis Peritoneal Cancer Dealing with Pollen Allergy Pleurectomy Immune Checkpoint Inhibitors for Cancer Treatment 

Recommended Reading
CAR T-Cell Therapy
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ......
Shrink Brain Tumors With Combination Immunotherapy
Brain metastases that occur during late-stage melanomas have shown a good response in more than ......
Novel Target Identified to Make Immunotherapy Effective in Triple Negative Breast Cancer
New protein target identified that might make immunotherapy with check-point inhibitors more ......
Gut Microbiome Influences Efficacy of Cancer Immunotherapy
Patients with melanoma treated with anti-PD1 drugs have their disease controlled, if they have a ......
Asbestosis
Asbestosis is a chronic inflammatory lung disease that occurs due to long term exposure to asbestos ...
Dealing with Pollen Allergy
The plants around you that give you sniffles in your nose at specific time of the year are the sourc...
Immune Checkpoint Inhibitors for Cancer Treatment
Immune checkpoint inhibitors are promising drugs to treat a variety of cancers and the FDA has appro...
Lung Cancer
Lung cancer is a malignant tumor in the lung tissues. Smoking is the main cause of lung cancer with ...
Mesothelioma
Mesothelioma is a rare, aggressive and deadly cancer of the mesothelial tissue lining the internal o...
Peritoneal Cancer
Peritoneal cancer is a rare cancer that develops in the peritoneum. Peritoneal cancers may be primar...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT A DOCTOR
I have read and I do accept terms of use - Telemedicine

Advantage Medindia: FREE subscription for 'Personalised Health & Wellness website with consultation' (Value Rs.300/-)